Clinical impact of serum exosomal microRNA in liver fibrosis.

<h4>Background/aim</h4>We investigated alterations in the expression of serum exosomal miRNAs with the progression of liver fibrosis and evaluated their clinical applicability as biomarkers.<h4>Methods</h4>This study prospectively enrolled 71 patients who underwent liver biop...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Young Chang, Jae-A Han, Suk Min Kang, Soung Won Jeong, Tom Ryu, Han Seul Park, Jeong-Ju Yoo, Sae Hwan Lee, Sang Gyune Kim, Young Seok Kim, Hong Soo Kim, So Young Jin, Seongho Ryu, Jae Young Jang
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/fc71d4d4e9af42979e8943f0b44d9f17
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fc71d4d4e9af42979e8943f0b44d9f17
record_format	dspace
spelling	oai:doaj.org-article:fc71d4d4e9af42979e8943f0b44d9f172021-12-02T20:08:22ZClinical impact of serum exosomal microRNA in liver fibrosis.1932-620310.1371/journal.pone.0255672https://doaj.org/article/fc71d4d4e9af42979e8943f0b44d9f172021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0255672https://doaj.org/toc/1932-6203<h4>Background/aim</h4>We investigated alterations in the expression of serum exosomal miRNAs with the progression of liver fibrosis and evaluated their clinical applicability as biomarkers.<h4>Methods</h4>This study prospectively enrolled 71 patients who underwent liver biopsy at an academic hospital in Korea. Exosomes were extracted from serum samples, followed by next-generation sequencing (NGS) of miRNAs and targeted real-time quantitative polymerase chain reaction. A model was derived to discriminate advanced fibrosis based on miRNA levels and the performance of this model was evaluated. Validation of the effect of miRNA on liver fibrosis in vitro was followed.<h4>Results</h4>NGS data revealed that exosomal miR-660-5p, miR-125a-5p, and miR-122 expression were changed significantly with the progression of liver fibrosis, of which miR-122 exhibited high read counts enough to be used as a biomarker. The level of exosomal miR-122 decreased as the pathologic fibrosis grade progressed and patients with biopsy-proven advanced fibrosis had significantly lower levels of exosomal miR-122 (P < 0.001) than those without advanced fibrosis. Exosomal miR-122 exhibited a fair performance in discriminating advanced fibrosis especially in combination with fibrosis-4 score and transient elastography. In a subgroup of patients with a non-viral etiology of liver disease, the performance of exosomal miR-122 as a biomarker was greatly improved. Inhibition of miR-122 expression increased the proliferation of the human hepatic stellate cell line, LX-2, and upregulated the expression of various fibrosis related proteins.<h4>Conclusion</h4>Exosomal miR-122 may serve as a useful non-invasive biomarker for liver fibrosis, especially in patients with non-viral etiologies of chronic liver disease.Young ChangJae-A HanSuk Min KangSoung Won JeongTom RyuHan Seul ParkJeong-Ju YooSae Hwan LeeSang Gyune KimYoung Seok KimHong Soo KimSo Young JinSeongho RyuJae Young JangPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 9, p e0255672 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Young Chang Jae-A Han Suk Min Kang Soung Won Jeong Tom Ryu Han Seul Park Jeong-Ju Yoo Sae Hwan Lee Sang Gyune Kim Young Seok Kim Hong Soo Kim So Young Jin Seongho Ryu Jae Young Jang Clinical impact of serum exosomal microRNA in liver fibrosis.
description	<h4>Background/aim</h4>We investigated alterations in the expression of serum exosomal miRNAs with the progression of liver fibrosis and evaluated their clinical applicability as biomarkers.<h4>Methods</h4>This study prospectively enrolled 71 patients who underwent liver biopsy at an academic hospital in Korea. Exosomes were extracted from serum samples, followed by next-generation sequencing (NGS) of miRNAs and targeted real-time quantitative polymerase chain reaction. A model was derived to discriminate advanced fibrosis based on miRNA levels and the performance of this model was evaluated. Validation of the effect of miRNA on liver fibrosis in vitro was followed.<h4>Results</h4>NGS data revealed that exosomal miR-660-5p, miR-125a-5p, and miR-122 expression were changed significantly with the progression of liver fibrosis, of which miR-122 exhibited high read counts enough to be used as a biomarker. The level of exosomal miR-122 decreased as the pathologic fibrosis grade progressed and patients with biopsy-proven advanced fibrosis had significantly lower levels of exosomal miR-122 (P < 0.001) than those without advanced fibrosis. Exosomal miR-122 exhibited a fair performance in discriminating advanced fibrosis especially in combination with fibrosis-4 score and transient elastography. In a subgroup of patients with a non-viral etiology of liver disease, the performance of exosomal miR-122 as a biomarker was greatly improved. Inhibition of miR-122 expression increased the proliferation of the human hepatic stellate cell line, LX-2, and upregulated the expression of various fibrosis related proteins.<h4>Conclusion</h4>Exosomal miR-122 may serve as a useful non-invasive biomarker for liver fibrosis, especially in patients with non-viral etiologies of chronic liver disease.
format	article
author	Young Chang Jae-A Han Suk Min Kang Soung Won Jeong Tom Ryu Han Seul Park Jeong-Ju Yoo Sae Hwan Lee Sang Gyune Kim Young Seok Kim Hong Soo Kim So Young Jin Seongho Ryu Jae Young Jang
author_facet	Young Chang Jae-A Han Suk Min Kang Soung Won Jeong Tom Ryu Han Seul Park Jeong-Ju Yoo Sae Hwan Lee Sang Gyune Kim Young Seok Kim Hong Soo Kim So Young Jin Seongho Ryu Jae Young Jang
author_sort	Young Chang
title	Clinical impact of serum exosomal microRNA in liver fibrosis.
title_short	Clinical impact of serum exosomal microRNA in liver fibrosis.
title_full	Clinical impact of serum exosomal microRNA in liver fibrosis.
title_fullStr	Clinical impact of serum exosomal microRNA in liver fibrosis.
title_full_unstemmed	Clinical impact of serum exosomal microRNA in liver fibrosis.
title_sort	clinical impact of serum exosomal microrna in liver fibrosis.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/fc71d4d4e9af42979e8943f0b44d9f17
work_keys_str_mv	AT youngchang clinicalimpactofserumexosomalmicrornainliverfibrosis AT jaeahan clinicalimpactofserumexosomalmicrornainliverfibrosis AT sukminkang clinicalimpactofserumexosomalmicrornainliverfibrosis AT soungwonjeong clinicalimpactofserumexosomalmicrornainliverfibrosis AT tomryu clinicalimpactofserumexosomalmicrornainliverfibrosis AT hanseulpark clinicalimpactofserumexosomalmicrornainliverfibrosis AT jeongjuyoo clinicalimpactofserumexosomalmicrornainliverfibrosis AT saehwanlee clinicalimpactofserumexosomalmicrornainliverfibrosis AT sanggyunekim clinicalimpactofserumexosomalmicrornainliverfibrosis AT youngseokkim clinicalimpactofserumexosomalmicrornainliverfibrosis AT hongsookim clinicalimpactofserumexosomalmicrornainliverfibrosis AT soyoungjin clinicalimpactofserumexosomalmicrornainliverfibrosis AT seonghoryu clinicalimpactofserumexosomalmicrornainliverfibrosis AT jaeyoungjang clinicalimpactofserumexosomalmicrornainliverfibrosis
_version_	1718375220313587712

Clinical impact of serum exosomal microRNA in liver fibrosis.

Ejemplares similares